Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 4
2008 1
2009 6
2010 6
2011 6
2012 2
2013 7
2014 11
2015 5
2016 14
2017 7
2018 15
2019 7
2020 10
2021 12
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
Cherney DZI, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Powell DR, Davies MJ, Banks P, Agarwal R. Cherney DZI, et al. Diabetes Obes Metab. 2023 Jun;25(6):1646-1657. doi: 10.1111/dom.15019. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36782093 Clinical Trial.
AIM: To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium-glucose co-transporters 1 and 2, in adults with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD3). MATERIALS AND METHODS: This phase 3, randomiz …
AIM: To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium-glucose co-transporters 1 and 2, in adults with type 2 d …
Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study.
Tangri N, Peach EJ, Franzén S, Barone S, Kushner PR. Tangri N, et al. Adv Ther. 2023 Jun;40(6):2869-2885. doi: 10.1007/s12325-023-02482-5. Epub 2023 May 3. Adv Ther. 2023. PMID: 37133647 Free PMC article.
Recorded diagnosis of stage 3 CKD is an important first step to reduce the risk of disease progression and minimize adverse clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT04847531. ...We found that healthcare teams prescribed significantly …
Recorded diagnosis of stage 3 CKD is an important first step to reduce the risk of disease progression and minimize adverse clinical …
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Bain SC, Mosenzon O, Arechavaleta R, Bogdański P, Comlekci A, Consoli A, Deerochanawong C, Dungan K, Faingold MC, Farkouh ME, Franco DR, Gram J, Guja C, Joshi P, Malek R, Merino-Torres JF, Nauck MA, Pedersen SD, Sheu WH, Silver RJ, Tack CJ, Tandon N, Jeppesen OK, Strange M, Thomsen M, Husain M. Bain SC, et al. Diabetes Obes Metab. 2019 Mar;21(3):499-508. doi: 10.1111/dom.13553. Epub 2018 Nov 11. Diabetes Obes Metab. 2019. PMID: 30284349 Free PMC article. Clinical Trial.
AIMS: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon-like peptide-1 receptor agonist. MATERIALS AND METHODS: PIONEER 6 is a multinational, randomized, placebo-controlled, double-blind trial in patients with t …
AIMS: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon-like peptide-1 receptor agoni …
Use of metformin in diseases of aging.
Miles JM, Rule AD, Borlaug BA. Miles JM, et al. Curr Diab Rep. 2014 Jun;14(6):490. doi: 10.1007/s11892-014-0490-4. Curr Diab Rep. 2014. PMID: 24752835 Free PMC article. Review.
Evidence has accumulated indicating that metformin is safe in people with stage 3 chronic kidney disease (CKD-3). It is estimated that roughly one-quarter of people with CKD-3 and T2DM in the United States (well over 1 million) are ineligible fo …
Evidence has accumulated indicating that metformin is safe in people with stage 3 chronic kidney disease …
METFORMIN: NONGLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS.
Anabtawi A, Miles JM. Anabtawi A, et al. Endocr Pract. 2016 Aug;22(8):999-1007. doi: 10.4158/EP151145.RA. Endocr Pract. 2016. PMID: 27579542 Review.
METHODS: Review of the literature, with a focus on metformin use in Stage 3 chronic kidney disease (CKD-3) and heart failure (HF). RESULTS: The United Kingdom Prospective Diabetes Study suggests that metformin reduces the risk of myocardial infa …
METHODS: Review of the literature, with a focus on metformin use in Stage 3 chronic kidney disease (CKD-3 …
Allopurinol Against Progression of Chronic Kidney Disease.
Golmohammadi S, Almasi A, Manouchehri M, Omrani HR, Zandkarimi MR. Golmohammadi S, et al. Iran J Kidney Dis. 2017 Jul;11(4):286-293. Iran J Kidney Dis. 2017. PMID: 28794291 Free article. Clinical Trial.
The aim of this study was to evaluate the effect of allopurinol on chronic kidney disease progression. MATERIALS AND METHODS: In a clinical trial, patients with stages 3 and 4 of chronic kidney disease were divided into two groups to receive allopurinol, 100 mg, dai …
The aim of this study was to evaluate the effect of allopurinol on chronic kidney disease progression. MATERIALS AND METHODS: In a clinic …
Determinants and Incidence of Chronic Kidney Disease with Tenofovir- Based Antiretroviral Therapy Regimens: A Cohort Study in HIV-Infected Adults in South China.
Liu F, Wang Y, Liu H, Chen C, Miao LB, Li ZY, Wang MC, Huang JS, Bao JF. Liu F, et al. Curr HIV Res. 2022;20(3):242-250. doi: 10.2174/1570162X20666220428105300. Curr HIV Res. 2022. PMID: 36111752
OBJECTIVE: The study aims to evaluate the incidence and risk factors of stage 3 chronic kidney disease (CKD) and rapid kidney function decline (RKFD) among Chinese HIV-1 infected patients starting with a TDF-based regimen. ...
OBJECTIVE: The study aims to evaluate the incidence and risk factors of stage 3 chronic kidney disease (C …
Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens.
Zachor H, Machekano R, Estrella MM, Veldkamp PJ, Zeier MD, Uthman OA, Taljaard JJ, Moosa MR, Nachega JB. Zachor H, et al. AIDS. 2016 May 15;30(8):1221-8. doi: 10.1097/QAD.0000000000001041. AIDS. 2016. PMID: 26836786 Free PMC article.
OBJECTIVE: To describe the incidence of rapid kidney function decline (RKFD), and stage 3 chronic kidney disease (CKD) in HIV-1-infected adults initiated on tenofovir-containing antiretroviral therapy. ...
OBJECTIVE: To describe the incidence of rapid kidney function decline (RKFD), and stage 3 chronic kidney dise …
Premature coronary artery disease and early stage chronic kidney disease.
Price AM, Ferro CJ, Hayer MK, Steeds RP, Edwards NC, Townend JN. Price AM, et al. QJM. 2018 Oct 1;111(10):683-686. doi: 10.1093/qjmed/hcx179. QJM. 2018. PMID: 29024966 Free PMC article. Review.
A 30 year old asymptomatic male with stage 3 chronic kidney disease (CKD) secondary to Focal Segmental Glomerulosclerosis was found to have features of CKD associated cardiomyopathy including left ventricular hypertrophy (LVH) and focal sub-endo …
A 30 year old asymptomatic male with stage 3 chronic kidney disease (CKD) secondary to Focal Segmental Gl …
Development and Validation of a Chronic Kidney Disease Prediction Model for Type 2 Diabetes Mellitus in Thailand.
Tuntayothin W, Kerr SJ, Boonyakrai C, Udomkarnjananun S, Chukaew S, Sakulbumrungsil R. Tuntayothin W, et al. Value Health Reg Issues. 2021 May;24:157-166. doi: 10.1016/j.vhri.2020.10.006. Epub 2021 Mar 2. Value Health Reg Issues. 2021. PMID: 33662821 Free article.
OBJECTIVES: The objective of this study was to investigate predictors and develop risk equations for stage-3 chronic kidney disease (CKD) in Thai patients with type 2 diabetes mellitus (DM). ...These stage-3 CKD prediction models could equip hea …
OBJECTIVES: The objective of this study was to investigate predictors and develop risk equations for stage-3 chronic …
114 results